July 27, 2026 11:17 AM EDT

Map­Light’s schiz­o­phre­nia drug damp­ens once-dai­ly hopes de­spite Phase 2 win

Ayisha Sharma

News Reporter

Map­Light Ther­a­peu­tics’ stock $MPLT plum­met­ed more than 60% on Mon­day af­ter a once-dai­ly reg­i­men of its schiz­o­phre­nia drug missed the pri­ma­ry end­point in a mid-stage …